trending Market Intelligence /marketintelligence/en/news-insights/trending/0W2rFjTOUblr2ynXDm4Ehw2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

OncoSec undertakes 1-for-10 reverse stock split


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

OncoSec undertakes 1-for-10 reverse stock split

Pennington, N.J.-based cancer drug developer OncoSec Medical Inc.'s board approved a 1-for-10 reverse stock split of its common stock, effective May 20.

The move reduced the company's issued and outstanding common shares to about 7 million from approximately 70 million.

OncoSec's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market under the ticker ONCS, effective May 21.